Jörn M. Schattenberg is a Professor of Medicine and Director of the Department of Medicine II at the University Medical Center Homburg and University of the Saarland in Germany. He received his medical degree in 2002 after studying at the University of Mainz (Germany) and at the Tulane University in New Orleans (US). He completed his post-doctoral training at the Albert-Einstein College of Medicine, New York, where he focused on delineating signalling pathways involved in the pathophysiology of acute and chronic liver injury with a special focus on metabolic liver disease and non-alcoholic steatohepatitis (NASH).
He is board-certified in Internal Medicine and Gastroenterology & Hepatology and Infectious Disease. His research focuses on translational sciences and clinical trials in Hepatology. He is involved in multinational, EU-funded research consortia exploring new technologies and approaches for the prevention and screening of metabolic liver disease and the development of novel biomarkers.
Professor Schattenberg is member of the Policy, Public Health and Advocacy Committee of the European Association for the Study of the Liver (EASL), a member of the Editorial Board of Hepatology and the Alimentary Pharmacology & Therapeutics and an Associate Editor of JHEP Reports.
